Licensing revenue narrows Aligos' Q2 loss, but cash runway shrinks to Q4 2026 — going concern warning stands
ALGS is trading near its 52-week low of $3.98 (14% above the low).
Summary
Aligos narrowed its Q2 loss to $1.5M on $27.8M in licensing revenue, but cash runway only extends into Q4 2026, triggering a going concern warning. The company needs immediate financing to continue operations.
Key Events · Earnings and Guidance · ALGS
-
Going Concern Warning Reiterated
Cash and equivalents of $30.4M plus $25M Amoytop payment fund operations only into Q4 2026 — less than one year. Management states substantial doubt about ability to continue as a going concern.
-
Q2 Loss Narrows on Licensing Revenue
Net loss of $1.5M vs. $15.9M a year ago, driven by $27.8M in licensing revenue from the Amoytop deal for pevifoscorvir sodium in Greater China.
-
R&D Spending Surges on Pivotal Trial
R&D expenses rose 72% YoY to $24.1M in Q2, primarily due to enrollment and dosing in the Phase 2 B-SUPREME study of pevifoscorvir sodium.
-
Cash Burn Accelerates
Operating cash outflow was $48.1M in H1 2026, up from $36.4M a year ago. Total assets fell to $66.3M from $88.5M at year-end 2025.
Analysis · ALGS · Life Sciences
A $27.8 million licensing payment from the Amoytop deal for pevifoscorvir sodium slashed Aligos' Q2 net loss to just $1.5 million. Yet the cash burn tells a starker story: $48 million in operating cash went out the door in the first half of 2026, leaving only $30.4 million on hand. Even after factoring in the $25 million Amoytop payment received in July, management warns the runway extends only into Q4 2026 — less than a year from this filing. The going concern warning is explicit and urgent. R&D costs jumped 72% as the pivotal Phase 2 B-SUPREME trial enrolled patients, and without new financing, Aligos may be forced to cut staff and delay programs. The stock, at $4.52, reflects deep distress — the company must raise capital imminently or face a restructuring.
At the time of this filing, ALGS was trading at $4.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.3M. The 52-week trading range was $3.98 to $13.69. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.